D5 receptor Inhibitors
1 drugsAbout D5 receptor
The D5 receptor is a dopamine receptor subtype and G protein-coupled receptor (GPCR) in the central nervous system (CNS). It mediates intracellular signaling pathways in response to dopamine, a neurotransmitter involved in neurological processes.
The D5 receptor represents a potential drug target within the CNS, though research lags behind other dopamine receptors. Currently, there is no genetic evidence available linking the D5 receptor to specific diseases.
ONAPGO is the only FDA-approved drug targeting the D5 receptor, approved in 2025. It is a small molecule developed by MDD US for CNS indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Postoperative Pain Management with only 2 trials.
Top D5 receptor Drugs
MDD US is the only company with an approved drug targeting the D5 receptor.
Low competition suggests a first-mover advantage, but also highlights potential challenges in market validation.
D5 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets D5 receptor, using small molecule modality.
The absence of other modalities indicates a whitespace opportunity for novel biologics targeting the D5 receptor.
D5 receptor Clinical Trials 9 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 | 0% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
D5 receptor Drug Approval Timeline (2025 - 2025)
The first and only drug, ONAPGO, was approved in 2025.
Recent approval suggests renewed interest in the target, but it is too early to assess market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 138 clinical trials targeting D5 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities